Zobrazeno 1 - 10
of 13
pro vyhledávání: '"Laura R. Parham"'
Autor:
Laura R. Parham, Michael E. Wechsler, Benjamin A. Raby, Steven W. Yancey, Lynn D. Condreay, Xiaoyan A. Qu, Soumitra Ghosh, Jonathan Steinfeld
Publikováno v:
Rheumatology International
Treatment of patients with the rare disease eosinophilic granulomatosis with polyangiitis (EGPA) with mepolizumab, a monoclonal antibody to interleukin-5 (IL-5) that reduces blood eosinophil counts, as an add-on therapy to glucocorticoid treatment, r
Autor:
Susan L. Ford, Laura R. Parham, William Spreen, Yu Lou, Kalpana Bakshi, Karen S. King, Kenneth Sutton, David A. Margolis, Parul Patel, Arlene R Hughes, Zhengyu Xue
Publikováno v:
Journal of Antimicrobial Chemotherapy
Background Cabotegravir is an HIV integrase inhibitor in clinical development with both oral and long-acting (LA) injectable formulations. Cabotegravir is primarily metabolized by uridine 5′-diphospho-glucuronosyltransferase (UGT) 1A1, a known poly
Autor:
Julie R. Gralow, Ajay O. Mehta, L. P. Briley, Lyndsay Harris, L. Warren, E. A. Perez, Georgia Demetriou, Julie Byrne, Masakazu Toi, Colin F. Spraggs, Martine Piccart, JoAnne Zujewski, Zeba Aziz, A Armour, S. Ahmed, Martin Andersson, Laura R. Parham, L. S. Williams, Z-f Jiang, N. Jackson, R. Crescenzo, D. J. Fraser
Publikováno v:
The Pharmacogenomics Journal. 18:480-486
HLA-DRB1*07:01 allele carriage was characterised as a risk biomarker for lapatinib-induced liver injury in a large global study evaluating lapatinib, alone and in combination with trastuzumab and taxanes, as adjuvant therapy for advanced breast cance
Autor:
Megan M. McLaughlin, Mindy Magee, Angie Gress, Ronald P. Danis, Li Ye, Philip J. Rosenfeld, Brian Berger, Laura R. Parham, Elias Reichel
Publikováno v:
Ophthalmology. Retina. 2(10)
Purpose To investigate the efficacy of intravenous GSK933776, a humanized monoclonal antibody directed against the N-terminal amino acids of amyloid β, for the treatment of geographic atrophy (GA) in age-related macular degeneration (AMD). Design Pr
Autor:
Karen S. King, Colin F. Spraggs, Paul J. Newcombe, Gil McVean, Zamin Iqbal, A J Slater, Matthew R. Nelson, Alexander T. Dilthey, Judong Shen, Linda P. Briley, Li Li, Charles J. Cox, Laura R. Parham
Publikováno v:
The Pharmacogenomics Journal
Lapatinib is associated with a low incidence of serious liver injury. Previous investigations have identified and confirmed the Class II allele HLA-DRB1*07:01 to be strongly associated with lapatinib-induced liver injury; however, the moderate positi
Autor:
Shannon K. McDonnell, Joan Curran, Dianne M. Finkelstein, Lon R. Cardon, Charles J. Cox, E. Rappold, Laura R. Parham, Bent Ejlertsen, Daniel J. Schaid, Colin F. Spraggs, Paul E. Goss
Publikováno v:
Journal of Clinical Oncology. 32:2296-2303
Purpose Liver injury is a serious adverse event leading to permanent discontinuation of lapatinib in affected patients. This study aimed to validate previously associated major histocompatibility complex (MHC) variants as predictors of risk of liver
Autor:
Linda P. Briley, Laura R. Parham, Paul E. Goss, Karen S. King, E. Rappold, Julie Byrne, Colin F. Spraggs
Publikováno v:
Pharmacogenomics. 16:1227-1229
Rash is a common side effect of lapatinib treatment. Since human leukocyte antigen (HLA) alleles have been implicated in multiple drug-induced cutaneous reactions, this study investigated the association of HLA alleles with lapatinib-induced rash. 11
Autor:
A. du Bois, Laura R. Parham, L. P. Briley, Mark W. Russo, Colin F. Spraggs, Toby Johnson, Kijoung Song, Chun-Fang Xu, Hiroomi Tada
Publikováno v:
Annals of Oncology. 26:1515-1517
Publikováno v:
Clinical pharmacology and therapeutics. 91(4)
Lapatinib is a clinically important component of the treatment for HER2-positive metastatic breast cancer and has an acceptable safety profile. Lapatinib-associated Hy's Law cases have been characterized using human leukocyte antigen (HLA) DQA1*02:01
Autor:
Julie Byrne, Colin F. Spraggs, L. S. Williams, Julie R. Gralow, Zeba Aziz, A Armour, Zhongsheng Tong, Masakazu Toi, Liling Warren, Ajay O. Mehta, L. P. Briley, Zefei Jiang, Nicola Jackson, Lyndsay Harris, Rocco Crescenzo, Shun D. Moodley, Martin Andersson, Dana Fraser, Laura R. Parham
Publikováno v:
Journal of Clinical Oncology. 33:617-617
617 Background: ALTTO (NCT00490139) is a large adjuvant breast cancer (ABC) study evaluating lapatinib, alone and in combinations with trastuzumab and taxanes. Characterization of hepatic abnormali...